Advanced search
Publication Cover
Cancer Investigation Volume 28, 2010 - Issue 8
Submit an article Journal homepage
149
Views
5
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEClinical Translational Therapeutics

A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer

Denise A. YardleySarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA
,
Davey DanielSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA
,
Michael StipanovSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA
,
D. Randolph DrosickSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA
,
Mark MainwaringSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA
,
James PeytonSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA
,
Mythili ShastrySarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA
&
John D. HainsworthSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA
 show all
Pages 865-871 | Published online: 06 Aug 2010
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

We investigated the feasibility/efficacy of oxaliplatin in combination with trastuzumab as first-/second-line treatment of HER2-positive metastatic breast cancer (MBC). Patients received oxaliplatin/trastuzumab every 21 days and were evaluated every 6 weeks using RECIST criteria. The study closed early due to slow accrual. Twenty-five patients were evaluable; of these, 5 (20%) had objective responses to oxaliplatin/trastuzumab. Therapy was well tolerated (no grade-4 and gastrointestinal grade-3 toxicity in 4% of patients), but had only modest activity (median time-to-progression 1.8 months). Substitution of oxaliplatin for cisplatin or carboplatin, in combination with trastuzumab, does not appear to improve first-/second-line therapy in HER2-positive MBC.

Appendix—Sarah Cannon Research Consortium Participating Sites

Table

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.